PDIA5

Across TCGA pan-cancer cohorts, PDIA5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDIA5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PDIA5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDIA5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where PDIA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	14	view →
CCRCC	OS	Quartile	All	0.722	0.954	.012	10	view →
GBM	OS	Quartile	All	0.320	0.687	.001	10	view →
LSCC	DFS	Quartile	All	0.896	1.000	.033	3	view →
HNSC	DFS	Tertile	III,IV	0.824	0.690	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDIA5–LUAD (OS)

Open the LUAD breakdown →